BIVI
BioVie Inc.·Healthcare
1.35
6.250%(−0.09)
Market ClosedLast Updated: — ET
52W L: $1.0652W H: $13.20
BIVI NEWS
proactiveinvestors.com
7h ago
BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson's disease, with CEO Cuong Do highlighting the company's focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while Parkinson's is commonly associated with dopamine deficiency and loss of muscle control, this represents only part of the disease mechanism.
proactiveinvestors.com
Mar 26
BioVie targets Parkinson's at its source with lead drug bezisterim
For decades, treatment of Parkinson's disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease's hallmark motor symptoms. But while therapies such as levodopa can temporarily restore movement, they do little to address the underlying neurodegeneration, and often introduce complications of their own.
proactiveinvestors.com
Mar 26
BioVie targets Parkinson’s at its source with lead drug bezisterim
For decades, treatment of Parkinson’s disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease’s hallmark motor...
proactiveinvestors.com
Mar 13
Nasdaq, S&P 500 in the red as investors digest slower GDP and steady inflation
4:05pm: In the red US stocks remained under pressure on Friday afternoon as investors reacted to new data indicating slowing economic growth amid the...
proactiveinvestors.com
Mar 12
Dow slides as oil prices hit triple digits amid Iran tensions
4:15pm: Tech stocks take hit Wall Street plunged Thursday as Middle East tensions sent oil soaring past $100 a barrel, stoking fears of a wider conflict and...
proactiveinvestors.ca
Mar 12
BioVie to present Parkinson's study data at AD/PD 2026 conference
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting. The conference is scheduled to take place March 17 to 21, 2026, in Copenhagen, Denmark.
